Citation Impact
Citing Papers
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
2005 StandoutScience
Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
2009 Standout
Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding
2011
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers
2013 Standout
Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis
2018
Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
2011
Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
2009 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
2012 Standout
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
A Randomized, Phase II Study of Preoperative plus Postoperative Imatinib in GIST: Evidence of Rapid Radiographic Response and Temporal Induction of Tumor Cell Apoptosis
2008
Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?
2009
Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.
1994
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
2009 Standout
Combination of Zoledronic Acid and Targeted Therapy Is Active But May Induce Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Carcinoma
2013
Establishing the Diagnosis of Lung Cancer
2013 Standout
Gastrointestinal Stromal Tumors II: Medical Oncology and Tumor Response Assessment
2009
Gastrointestinal stromal tumour
2007
Cancer to bone: a fatal attraction
2011 Standout
Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib
2005
Cancer Stem Cells: Impact, Heterogeneity, and Uncertainty
2012 Standout
Simultaneous Quantification of Erlotinib, Gefitinib, and Imatinib in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry
2009
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
2017 StandoutNobel
ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)
2009 Standout
Role of platelet-derived growth factors in physiology and medicine
2008 Standout
Cancer drug resistance: an evolving paradigm
2013 Standout
Results of Tyrosine Kinase Inhibitor Therapy Followed by Surgical Resection for Metastatic Gastrointestinal Stromal Tumor
2007
Chemical biology of natural indolocarbazole products: 30 years since the discovery of staurosporine
2009 StandoutNobel
Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias
2006 Standout
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability
2008
Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma
2002
Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial
2007
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
2006 Standout
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
2010 StandoutNature
Impact of Surgery on Advanced Gastrointestinal Stromal Tumors (GIST) in the Imatinib Era
2006
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
2010 Standout
Mechanisms of bone invasion and metastasis in human neuroblastoma
2005
Anticancer activities of histone deacetylase inhibitors
2006 Standout
Role of proinflammatory cytokines in the pathophysiology of osteoarthritis
2010 Standout
Bisphosphonate-induced osteonecrosis of the jaws: Prospective study of 80 patients with multiple myeloma and other malignancies
2008
Killing time for cancer cells
2005
Drug Insight: gastrointestinal stromal tumors (GIST)—the solid tumor model for cancer-specific treatment
2008
Randomized Phase III Trial of Dose-Dense Chemotherapy Supported by Whole-Blood Hematopoietic Progenitors in Better-Prognosis Small-Cell Lung Cancer
2005
Gastrointestinal stromal tumor: 5 years later
2005
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
2009
Cellular processing of platinum anticancer drugs
2005 Standout
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665
2008
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Translation of new cancer treatments from pet dogs to humans
2008 Standout
Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs)
2008
Acne vulgaris
2011 Standout
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
2004 Standout
Drug-Induced Skin, Nail and Hair Disorders
2007
Chemotherapy as treatment of primary and recurrent small cell lung cancer
2001
The role of zoledronic acid in cancer: Clinical studies in the treatment and prevention of bone metastases
2001
Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer
2001
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
2005 Standout
Lenograstim as Support for ACE Chemotherapy of Small-Cell Lung Cancer
2000
Metastasis to bone: causes, consequences and therapeutic opportunities
2002 Standout
Microenvironmental regulation of metastasis
2008 Standout
Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain
2002
Standard Versus Intensified Chemotherapy With Granulocyte Colony-Stimulating Factor Support in Small-Cell Lung Cancer: A Prospective European Organization for Research and Treatment of Cancer–Lung Cancer Group Phase III Trial—08923
2002
Microtubules as a target for anticancer drugs
2004 Standout
The biopsychosocial approach to chronic pain: Scientific advances and future directions.
2007 Standout
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
Clinical pharmacokinetics of tyrosine kinase inhibitors
2009
Mechanisms of Bone Metastasis
2004 Standout
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo
1993
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
2010 Standout
Cytoreductive Surgery in Patients with Metastatic Gastrointestinal Stromal Tumor Treated with Sunitinib Malate
2009
Gastrointestinal Stromal Tumors
2005
The Clavien-Dindo Classification of Surgical Complications
2009 Standout
New functions for the matrix metalloproteinases in cancer progression
2002 Standout
The cancer genome
2009 StandoutNature
Small-cell lung cancer
2011
Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer
2003
Remarkable Potential of the α-Aminophosphonate/Phosphinate Structural Motif in Medicinal Chemistry
2011
Spectrum of Activity and Mechanism of Action of VEGF/PDGF Inhibitors
2007
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
2004
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
2014 Standout
Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study
2008
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
2020 Standout
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
2009 Standout
Bisphosphonate treatment inhibits the growth of prostate cancer cells.
2001
Copper-Catalyzed Synthesis of Mixed Alkyl Aryl Phosphonates
2014 StandoutNobel
Surgical Management of Advanced Gastrointestinal Stromal Tumors After Treatment With Targeted Systemic Therapy Using Kinase Inhibitors
2006
Absence of Progression As Assessed by Response Evaluation Criteria in Solid Tumors Predicts Survival in Advanced GI Stromal Tumors Treated With Imatinib Mesylate: The Intergroup EORTC-ISG-AGITG Phase III Trial
2009
Natural Killer Cell IFN-γ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor–Bearing Patients
2009
Surgery of Residual Disease Following Molecular-targeted Therapy With Imatinib Mesylate in Advanced/Metastatic GIST
2007
Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation
2005
Molecular Genetics of Acute Lymphoblastic Leukemia
2005
Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors
2009
Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.
2000
Liquid Biopsies: Genotyping Circulating Tumor DNA
2014 Standout
Indications for Imatinib Mesylate Therapy and Clinical Management
2004
Proteomic Analysis to Identify Breast Cancer Biomarkers in Nipple Aspirate Fluid
2004
Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure
2007
American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update
2014 Standout
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Works of P. Berthaud being referenced
Phase I–II study of vinorelbine (Navelbine®) plus cisplatin in advanced non-small cell lung cancer
1992
Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: A prospective study of 54 patients
2003
Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec®) in vitro and in vivo
2003
Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study.
1997
Quantification of Imatinib in Human Plasma by High-Performance Liquid Chromatography-Tandem Mass Spectrometry
2005
Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: Rationale and design of phase I/II trials
2003
Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer
2004
Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase
2003
Imatinib for the treatment of aggressive fibromatosis (desmoid tumors) failing local treatment. A phase II trial of the French Sarcoma Group
2006
[Results of a phase II study of the combination of cis-platinum and 5-FU in epidermoid or undifferentiated large cell bronchial cancer].
1989
Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group
2007
Pharmacokinetic-Pharmacodynamic Relationships of Imatinib and Its Main Metabolite in Patients with Advanced Gastrointestinal Stromal Tumors
2006
Continuous vs intermittent imatinib treatment in advanced GIST after one year: A prospective randomized phase III trial of the French Sarcoma Group
2004
Zoledronate Is a Potent Inhibitor of Myeloma Cell Growth and Secretion of IL-6 and MMP-1 by the Tumoral Environment
1999
Interruption of imatinib (IM) in GIST patients with advanced disease: Updated results of the prospective French Sarcoma Group randomized phase III trial on survival and quality of life
2005
Continuous vs intermittent imatinib treatment in advanced GIST after one year: A prospective randomized phase III trial of the French Sarcoma Group
2004